Skip to content

Search Results

No Matching Results

    Recently Viewed


      HomeLatest newsWhat you need to know about Johnson & Johnson’s 2018 first-quarter earnings
      FINAL LEDE - What You Need to Know about Johnson & Johnson's 2018 First-Quarter Earnings - small people illo

      What you need to know about Johnson & Johnson’s 2018 first-quarter earnings

      Learn how the company’s consumer, pharmaceutical and medical devices businesses performed in the first quarter of 2018 in this recap of Johnson & Johnson’s latest earnings report.

      Share Article
      share to

      Johnson & Johnson shared financial information this morning about its first-quarter performance in 2018.

      Since its founding in 1886, the company has grown to become one of the world’s largest and most broadly based healthcare companies, with approximately 135,000 employees across the globe working every day to help change the trajectory of health for humanity.

      For more details about the company’s first-quarter 2018 results, and to read a message from Chairman and Chief Executive Officer Alex Gorsky, here’s an infographic packed with key stats.

      2018 First-Quarter Earnings infographic

      Johnson & Johnson’s 2018 1st-Quarter Earnings

      Read the earnings press release, which includes full financial data for the first quarter of the year.

      Want to see more company earnings information? Find several years of Johnson & Johnson quarterly and full-year results here.

      More from Johnson & Johnson

      Meet a nurse who leads clinical trials to find innovative cancer therapies

      Melissa Martinez is a clinical scientist within Johnson & Johnson’s Interventional Oncology R&D group. Not only is she helping to develop lifesaving treatments, she’s redefining what it means to pursue a career in nursing.

      What’s the difference between IBS and IBD?

      These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.

      What is IL-23?

      This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat autoimmune conditions such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.
      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.